Equities research analysts expect that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will post earnings per share of ($0.24) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Oramed Pharmaceuticals’ earnings, with estimates ranging from ($0.27) to ($0.19). Oramed Pharmaceuticals posted earnings of ($0.20) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 20%. The company is expected to report its next quarterly earnings results on Monday, April 22nd.
According to Zacks, analysts expect that Oramed Pharmaceuticals will report full-year earnings of ($0.99) per share for the current year, with EPS estimates ranging from ($1.05) to ($0.92). For the next financial year, analysts anticipate that the company will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.00) to ($0.98). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Oramed Pharmaceuticals.
Separately, HC Wainwright set a $25.00 price target on shares of Oramed Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, January 14th.
An institutional investor recently raised its position in Oramed Pharmaceuticals stock. BlackRock Inc. lifted its position in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 137.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 69,343 shares of the biotechnology company’s stock after buying an additional 40,114 shares during the period. BlackRock Inc. owned about 0.40% of Oramed Pharmaceuticals worth $208,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 10.50% of the company’s stock.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Further Reading: What are gap-down stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.